Precision Cancer Diagnostic Test Market Report 2024-2034

Precision Cancer Diagnostic Test Market Report 2024-2034

The Precision Cancer Diagnostic Test Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Adoption of Liquid Biopsies Propels Market Growth

The increasing adoption of liquid biopsies in cancer diagnosis has significantly intensified market competitiveness, with companies actively entering this domain viewed as key drivers of clinical advancements. LabCorp's introduction of a novel blood test in June 2023 for detecting cancer-related biomarkers exemplifies this trend, potentially expediting effective treatments. Liquid biopsy, particularly valuable for those unable to undergo tissue biopsies, is gaining traction, notably in diagnosing advanced and metastatic cancer cases. Breakthroughs, such as the detection of cancer in diverse bodily fluids through liquid biopsy in March 2022, highlight the technology's expanding applications. The ongoing development of non-invasive liquid biopsies focusing on circulating tumor DNA and other markers holds promise for transforming cancer diagnostics by enabling real-time monitoring and early detection. Industry efforts to integrate liquid biopsy with advanced AI technologies, as seen in collaborations like GC Genome Corporation with KAIST, underscore the commitment to enhancing DNA mutation analysis. Noteworthy company initiatives, including Qiagen's acquisition of Verogen and BillionToOne's precise liquid biopsy device launch, highlights the industry's focus on growth, technological advancements, and product innovation, driving market expansion.

Challenges Posed by High Cost of Precision Cancer Diagnostic Test

Precision cancer diagnostic tests utilize advanced technologies, such as next-generation sequencing (NGS) or mass spectrometry, which can be associated with high costs, posing challenges for accessibility, especially in resource-constrained regions. The elevated expenses linked to precision cancer diagnostics may act as a hindrance to market growth, restricting patient access to these advanced diagnostic tools. Despite the significant advantages offered by precision cancer diagnostics, including more accurate diagnoses and personalized treatment plans, the financial implications associated with these tests presents a formidable challenge for both healthcare systems and patients. For example, the FoundationOne CDx, priced at approximately US$5,800.0 per biopsy, delivers valuable information for treatment decisions but can impose a substantial financial burden on patients and healthcare systems. Guardant360, a liquid biopsy test by Guardant Health analyzing circulating tumor DNA, comes with a cost ranging from US$5,000 to US$6,500 per biopsy. While liquid biopsies are less invasive than tissue biopsies, their pricing remains a concern, potentially limiting access for certain patients, particularly those lacking comprehensive insurance coverage, and leading to potential delays in diagnosis and treatment decisions.

What Questions Should You Ask before Buying a Market Research Report?

• How is the precision cancer diagnostic test market evolving?
• What is driving and restraining the precision cancer diagnostic test market?
• How will each precision cancer diagnostic test submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each precision cancer diagnostic test submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading precision cancer diagnostic test markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the precision cancer diagnostic test projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of precision cancer diagnostic test projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the precision cancer diagnostic test market?
• Where is the precision cancer diagnostic test market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the precision cancer diagnostic test market today, and over the next 10 years:

• Our 370-page report provides 135 tables and 235 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the precision cancer diagnostic test market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising precision cancer diagnostic test prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product & Services Outlook

• Products
• Services

Test Type

• Cancer Imaging
- Computed Tomography

- Magnetic Resonance Imaging

- Digital & Analog Mammography

- Positron Emission Tomography

- Digital Breast Tomosynthesis

- Molecular Breast Imaging

- Others
• Molecular Cancer Testing
- Polymerase Chain Reaction (PCR)

- Next-Generation Sequencing (NGS)

- Liquid Biopsies

- Immunohistochemistry (IHC)

- Fluorescence In Situ Hybridization (FISH)

- Others
• Tumour Marker Immunoassays
• POC Colon Cancer Tests
• Others

Biopsy Method

• Liquid Biopsy
• Tissue Biopsy

Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Pancreatic Cancer
• Other Cancers

End-user

• Diagnostic Laboratories
• Hospitals
• Cancer Centers and Clinics
• Research Institutions

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Precision Cancer Diagnostic Test Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• Abbott
• Agilent Technologies, Inc.
• Bayer AG
• bioMérieux SA
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Myriad Genetics, Inc.
• QIAGEN N.V.
• Siemens Healthineers
• Thermo Fisher Scientific

Overall world revenue for Precision Cancer Diagnostic Test Market, 2024 to 2034 in terms of value the market will surpass US$12,097.8 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Precision Cancer Diagnostic Test Market, 2024 to 2034 report help you?

In summary, our 370-page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Precision Cancer Diagnostic Test Market, 2024 to 2034 Market, with forecasts for product, test type, application, biopsy method, and end-user, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 18 key national markets – See forecasts for the Precision Cancer Diagnostic Test Market, 2024 to 2034 market in North America, Europe, Asia Pacific, Latin America, and MEA. Also includes forecast for the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Precision Cancer Diagnostic Test Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Precision Cancer Diagnostic Test Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher..

The publisher is using a password system to access single user and team licenses. Single user (non-printable) and team licenses expire after 12 month period. In the case of team license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.